BPH treatment market seen reaching $11.29 billion by 2030

The benign prostatic hyperplasia treatment market is projected to grow from $8.69 billion in 2025 to $11.29 billion by 2030, driven by aging populations, wider use of minimally invasive procedures and more personalized care. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Benign prostatic hyperplasia, or BPH, affects aging men and can cause urinary problems that reduce quality of life. - Demand for treatments is rising as healthcare systems adopt more minimally invasive procedures and digital care tools. - The market outlook signals more spending on drugs, procedures and monitoring for prostate enlargement.

What happened: - The Business Research Company projected the global BPH treatment market will rise from $8.69 billion in 2025 to $9.17 billion in 2026. - The report expects the market to reach $11.29 billion by 2030. - The forecast implies a 5.6% compound annual growth rate from 2025 to 2026 and a 5.3% CAGR through 2030. - The company published the report as "The Business Research Company's Benign Prostatic Hyperplasia Treatment Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report includes a free sample and the full market report.

The details: - Historical growth was tied to an aging male population, higher rates of urinary disorders, more specialized urology services, wider use of pharmacological treatments and better access to diagnostic screening. - Forecast growth is linked to robotic-assisted prostate surgery, personalized treatment plans, home-based therapies, digital patient monitoring and stronger demand for minimally invasive procedures. - The report highlights a shift toward minimally invasive surgeries, targeted drug therapies, combined treatment approaches, more outpatient care and greater focus on symptom control. - BPH treatment includes medical, minimally invasive and surgical approaches designed to ease symptoms of enlarged prostate. - Common symptoms include frequent urination, weak urine flow and a feeling of incomplete bladder emptying. - Effective treatment matters because unmanaged BPH can contribute to urinary retention and related complications.

Between the lines: - The market forecast reflects a broader healthcare preference for less invasive care that shortens recovery and reduces complications. - The report points to a mix of procedural innovation and chronic-condition management as the main growth engine, not a single treatment breakthrough. - North America held the largest share of the global market in 2025, showing the impact of mature healthcare infrastructure and broad access to advanced therapies. - Asia-Pacific is expected to be the fastest-growing region over the forecast period, suggesting rising adoption as healthcare access expands. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company also added market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics, and updated technology and trend analysis to its 2026 reports. - The report cites September 2023 data from the American Society of Plastic Surgeons showing nearly 25.4 million minimally invasive cosmetic procedures in the U.S., up 7% from 23.7 million in 2022, as evidence of patient preference for less invasive care.

What's next: - The BPH market is likely to keep growing as older male populations expand and more patients seek symptom relief. - Robotic-assisted surgery, outpatient care and home-based monitoring may take a larger role in treatment pathways. - Regional growth in Asia-Pacific will be a key indicator of how quickly advanced BPH care spreads beyond mature markets. - The Business Research Company lists Saumya Sahay as a contact for expert discussions about the report.